All Oncology News

Marijo Bilusic, MD, PhD, highlights key points presented at the meeting, including considerations with PARP inhibitor combinations for patients with mCRPC, how disease characteristics factor into treatment selection for patients with hormone-sensitive prostate cancer, and more.

Mrinal M. Gounder, MD, discusses the rationale for investigating nirogacestat in the DeFi trial, highlights patient-reported outcomes with the agent in this study, and discusses potential next steps for better utilizing T2-weighted magnetic resonance imaging in addition to RECIST criteria when assessing tumor volume and dimensions in desmoid tumors.

Innovative new technologies being used exclusively by Florida Cancer Specialists & Research Institute, LLC in Ocala and The Villages are helping to target tumors more precisely, reduce side effects and enhance comfort for patients receiving radiation therapy for the treatment of certain cancers, including breast cancer and head and neck cancers.

Preliminary findings from the phase 3 BOND-003 trial showed that treatment with cretostimogene grenadenorepvec led to sustained and durable complete responses and a tolerable safety profile in patients with high-risk non-muscle invasive bladder cancer who are unresponsive to Bacillus Calmette-Guerin.

The FDA has granted priority review to a supplemental biologics license application for enfortumab vedotin plus pembrolizumab for the frontline treatment of patients with locally advanced or metastatic urothelial cancer.

This commentary examines the use of words and expressions in the oncology domain and the implications of different interpretations by patients and their families from professionals employing this language, including academic authors and members of their clinical teams.

Kathleen N. Moore, MD, MS, discusses the challenges with utilizing immune-targeted therapy for ovarian cancer, expands on the impact of the tumor microenvironment on the effectiveness of immune checkpoint inhibitors, and details ongoing research with different treatment approaches in ovarian cancer.

The triplet combination of sintilimab, chidamide, and bevacizumab resulted in a high 18-week progression-free survival rate with a favorable toxicity profile in patients with microsatellite stable or mismatch repair–proficient metastatic colorectal cancer, according to data from the phase 2 CAPability-01 trial.

Lyudmila A. Bazhenova, MD, expanded on key considerations when navigating the use of perioperative immunotherapy for patients with or without oncogenically-driven lung cancers, the importance of multidisciplinary collaboration when deciding on a treatment plan, and the need for increased and earlier implementation of biomarker testing in all patients with lung cancer.

Pembrolizumab continued to demonstrate at trend toward improved overall survival compared with chemotherapy in patients with microsatellite instability–high or mismatch repair–deficient metastatic colorectal cancer.

The FDA has granted fast track designation to zotatifin for use in combination with fulvestrant and abemaciclib as second- or third-line therapy for the treatment of patients with estrogen receptor-positive, HER2-negative advanced or metastatic breast cancer with disease progression following treatment with endocrine therapy and a CDK4/6 inhibitor.

Dolphins Challenge Cancer and AutoNation are teaming up to address the links between social, economic and environmental factors and breast cancer mortality.

Bradley J. Monk, MD, FACOG, FACS, and Paolo Tarantino, MD, discuss key data with B7-H4–directed antibody-drug conjugates across solid tumor types, the evolving role of antibody-drug conjugates in gynecologic cancers, and the importance of determining optimal sequencing with these agents in breast cancer.

With multiple antibody drug conjugate options now available for patients with HER2-negative metastatic breast cancer, clinicians must consider a variety of factors when selecting and sequencing therapies.

The FDA has granted clearance for an investigational new drug application for a phase 1/2 safety lead-in trial investigating the engineered tumor-infiltrating lymphocyte KSQ-001EX in patients with melanoma, head and neck squamous cell carcinoma, and non–small cell lung cancer.

Nadofaragene firadenovec-vncg led to encouraging rates of high-grade recurrence-free survival and overall survival in patients with high-risk, BCG-unresponsive non–muscle invasive bladder cancer with carcinoma in situ with or without papillary tumors.

Biagio Ricciuti, MD, discusses the need to improve the identification of patients with advanced non–small cell lung cancer that benefit most from immune checkpoint inhibition.

Perioperative enfortumab vedotin elicited responses in cisplatin-eligible patients with muscle-invasive bladder cancer.

Florida Cancer Specialists & Research Institute, LLC is pleased to announce that Bradley Monk, MD will join the statewide practice as Medical Director of Late-Phase Research, effective January 1, 2024.

Telisotuzumab vedotin produced meaningful response rates and other clinically relevant outcomes in patients with c-Met protein overexpressed, EGFR wild-type, advanced or metastatic nonsquamous non–small cell lung cancer.

Reena J. Salgia, MD, discusses the advantages of utilizing an atezolizumab plus bevacizumab backbone as standard frontline therapy in unresectable HCC; how factors such as Child-Pugh B score, bleeding, and other high-risk features impact treatment selection; and the unmet needs that still need to be addressed for this patient population.

The combination comprised of camrelizumab and famitinib showcased improved efficacy with a manageable safety profile vs camrelizumab monotherapy or investigator’s choice of chemotherapy in patients with recurrent or metastatic cervical cancer.

The Center for Drug Evaluation of China’s National Medical Products Administration has accepted and granted priority review to the new drug application for IBI351 in the treatment of patients with advanced, KRAS G12C–mutant NSCLC who have received at least 1 prior systemic therapy.

Nimotuzumab given concurrently with chemoradiotherapy demonstrated efficacy and favorable tolerability in patients with locally advanced cervical squamous cell carcinoma, according to data from a randomized, controlled, open-label, multicenter study.

Retifanlimab-dlwr continued to elicit responses with acceptable tolerability in patients with recurrent microsatellite instability–high or mismatch–repair deficient endometrial cancer, according to final findings from cohort H of the phase 1 POD1UM-101 trial.

Benjamin Philip Levy, MD, discusses the current landscape of emerging antibody-drug conjugates (ADCs) and their early activity in advanced lung cancer, the potential utility of oncogene-directed ADCs for patients with driver mutations, and more.

EG12014, a biosimilar of the anti-HER2 monoclonal antibody trastuzumab, has received a marketing authorization from the European Commission for use in the European Union for the treatment of patients with HER2-positive breast and metastatic gastric cancer; these are the same indications that trastuzumab holds in the EU.

New Cleveland Clinic research reveals how BRCA1 and BRCA2 gene mutations may impact cell communication in breast tissue, furthering the understanding of how cancer develops.

The frontline combination of cadonilimab and platinum-based chemotherapy with or without bevacizumab provided a progression-free survival benefit in patients with recurrent or metastatic cervical cancer.

Ehab L. Atallah, MD, highlights updates in chronic lymphocytic leukemia, emphasizing the importance of understanding the plethora of options that are present for oncologists treating patients within this population.